Using the NDB data from 1998 to 2011, we showed that RA patients tend to remain on their initial and second biologic (ie. Enbrel, Remicade, Humira, Orencia, Cimzia, Simponi, Actemra) for long periods suggesting the drugs are effective. The most common reason for stopping a biologic was due to side effects.

Worse overall health strongly predicted discontinuation. If patients noted higher amounts of health problems (ie. heart, liver, or kidney problems, etc.) and they smoked, they were more likely to discontinue their medication. Co-medication with methotrexate helped to lower discontinuation.

The research also showed that 
with more biologics to choose from, the impact of overall health on discontinuations lessened but discontinuation rates in patients who started their biologics since 2004 are higher due to having more options.